A patient with idiopathic myelofibrosis (IM) in the osteosclerotic phase received an allogeneic stem cell transplant. Hemopoietic engraftment was rapid, and full donor chimerism was observed on day +70. However, a few months later, replacement of donor hemopoiesis by the patient's 20q− cell clone was observed, followed by reappearance of the blood IM features, marrow fibrosis and osteosclerosis. At 8 months from transplant donor lymphocytes were infused, which induced chronic GVHD. This resulted in normalization of the blood, with disappearance of the fibrosis and osteosclerosis, effects which persisted 20 months later. This case provides evidence for a graft-versus-disease effect in IM. Bone Marrow Transplantation (2000) 26, 697-699. Keywords: idiopathic myelofibrosis; agnogenic myeloid metaplasia; allogeneic transplantation; donor lymphocyte infusion; graft-versus-host disease; graft-versus-disease effect Idiopathic myelofibrosis (IM), also known as agnogenic myeloid metaplasia, is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, extramedullary hemopoiesis, splenomegaly, and leukoerythroblastic blood picture, 1 with the fibrosis being a secondary phenomenon to the clonal proliferation of a stem cell common to the three hemopoietic cell lines.
Idiopathic myelofibrosis (IM), also known as agnogenic myeloid metaplasia, is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, extramedullary hemopoiesis, splenomegaly, and leukoerythroblastic blood picture, 1 with the fibrosis being a secondary phenomenon to the clonal proliferation of a stem cell common to the three hemopoietic cell lines. 2 Treatment of IM is palliative and consists mainly of administration of oral chemotherapy or androgens, depending on the disease characteristics of an individual patient, in addition to transfusion support. 3 Although IM is typically a disease of the elderly, almost a quarter of patients are 55 years old or younger. 4 In the latter patients allogeneic stem cell transplantation (allo-SCT) is a therapeutic alternative with the potential for cure. 5 In this setting, lack of graft-versus-hostdisease (GVHD) or the presence of only grade I GVHD has been demonstrated to be the main factor related to treatment failure after allo-SCT in IM. 5 This suggests that, as in other hematological malignancies, 6-8 a graft-versus-disease effect could play a role in the eradication of IM.
We report a patient in whom complete remission of IM was achieved following induction of GVHD by donor lymphocyte infusion after failure of allo-SCT.
Case report
A 48-year-old woman was referred to our center in January 1997. She had been diagnosed with IM in another hospital 18 months earlier, after the discovery of splenomegaly, anemia and thrombocytosis. The patient complained of malaise and sweats, and had had several splenic infarcts in the previous months. On physical examination, the spleen and liver were palpable at 20 and 6 cm below the respective costal margins. Hb was 11.3 g/dl (with anisopoikilocytosis, tear-drop cells, and 4% circulating erythroblasts per 100 leukocytes), WBC count was 12 × 10 9 /l (with 50% neutrophils, 15% band forms, 3% basophils, 8% lymphocytes, 7% monocytes, 4% metamyelocytes, 8% myelocytes and 5% blasts), platelet count was 513 × 10 9 /l, and serum LDH 1198 UI/l. A bone marrow aspirate yielded a dry tap, but cytogenetic study of unstimulated peripheral blood demonstrated the presence of a clone with the 20q− (q11q13) abnormality. A bone marrow biopsy disclosed decreased hemopoietic cellularity, with diffuse reticulin and collagen fibrosis, and osteosclerosis (Figure 1a) , confirming the diagnosis of IM at advanced histologic stage. A splenectomy was performed followed by an allogeneic peripheral blood progenitor cell transplant (allo-PBCT) from her HLA-compatible brother, in November 1997. After administration of busulfan (4 mg/kg p.o. daily for 4 days) and cyclophosphamide (60 mg/kg once daily i.v. for 2 days) as conditioning, 7.4 × 10 6 CD34 + cells/kg and 391 × 10 6 CD3 + cells/kg, obtained from the donor's unmodified peripheral blood were infused. Cyclosporin A and methotrexate (days +1, +3 and +6) were used as prophylaxis for GVHD. At day 13 post transplant, the patient developed a mild facial and plantar skin rash, corresponding to grade I GVHD, which disappeared in a few days following a short course of methylprednisolone (1 mg/kg/day). At day 20 post transplant, hematological recovery was observed, and 70 days from transplant, complete donor chimerism (46XY karyotype) was demonstrated on bone marrow cytogenetics. A further marrow biopsy performed 3 months from transplant showed a reduction in the osteosclerosis and disappearance of the collagen fibrosis, with persistence of the diffuse reticulin fibrosis. One month later, progression of IM was seen, with anemia, leukocytosis, leukoerythroblastic blood picture, thrombocytosis, and reappearance of the 46XX 20q− cell clone. In an attempt to induce a graftversus-disease effect, cyclosporin A was discontinued. However, since the patient did not develop signs of GVHD, a donor lymphocyte infusion (DLI) was planned. In June 1998, the patient received a total of 296 × 10 6 CD3 + cells/kg and 5.5 × 10 6 CD34 + cells/kg, obtained from the donor's peripheral blood after G-CSF administration. Two and a half months later, a mild, generalized skin rash developed, followed by the appearance of lichenoid oral and ocular lesions typical of chronic GVHD. Methylprednisolone (1 mg/kg/day) was given and cyclosporin A was restarted, resulting in good control, although without complete disappearance of the chronic GVHD. Concurrently with the appearance of the chronic GVHD, progressive normalization of the patient's blood features was noted. A bone marrow biopsy performed 6 months from DLI disclosed normal hemopoietic cellularity, with moderate reticulin fibrosis. The cyclosporin A dose was progressively tapered, until its total discontinuation 1 year after starting it. Currently, 28 months from allo-SCT and 20 months from DLI, the patient has slight oral and ocular signs of chronic GVHD, her peripheral blood has remained normal for the last 14 months, a recent marrow biopsy has displayed normal hemopoietic cellularity (Figure 1b ) with no fibrosis, and bone marrow cytogenetics show a 46XY karyotype in the 36 metaphases analyzed, whereas analysis of 10 short-tandem repeats by an automated method (AmpFISTR Plus; PE Biosystems, Foster City, CA, USA) shows complete donor chimerism in both T cells and granulocytes.
Discussion
Idiopathic myelofibrosis (IM), a more uncommon chronic myeloproliferative disorder, is a clonal hemopoietic stem cell disorder characterized by bone marrow fibrosis, extramedullary hemopoiesis, splenomegaly, and a leukoerythroblastic blood picture. The disease usually affects old people and is associated with a median survival ranging from 3.5 to 5 years. Currently, treatment of IM remains mostly palliative, since no significant prolongation in survival is achieved with the available therapeutical modalities. In a recent analysis including cases from four European institutions, 4 we observed that almost a quarter of IM patients were 55 years old, or younger, at presentation. Survival of these younger patients was substantially longer than that of the overall IM population, since their median survival exceeded 10. years. In such a subgroup of patients, the initial features associated with an unfavorable prognosis were the presence of constitutional symptoms, a Hb value р10 g/dl, and blast cells у1% in the peripheral blood. Based on the number of the latter three factors, two risk groups of younger IM patients were identified. Thus, median survival of patients with no, or only one bad prognostic factor approached 15 years, whereas the minority of patients with two or the three adverse prognostic factors survived for a median of less than 3 years.
Allo-SCT has emerged as a treatment with the potential for cure in younger patients with IM. Guardiola et al 5 analyzed the outcome of 55 IM patients younger than 55 years undergoing allo-SCT in 28 centers world-wide. Graft failure was 9%, 1-year probability of transplant-related mortality 27%, and 5-year probability of survival 47%. With a median post-transplant follow-up of 36 months, 22 of the 55 patients were in complete 'histohematologic' remission, with the 5-year probability of event-free survival being 39% for the overall group and 48% for those patients receiving an unmanipulated HLA matched related graft. When the factors influencing treatment failure were analyzed, lack of or a mild degree of GVHD were found to be the most important, followed by the presence of an abnormal karyotype at transplantation, and older age.
A graft-versus-disease effect has been demonstrated in several hematological malignancies [6] [7] [8] and a 60 to 73% response rate has been reported after donor lymphocyte infusion (DLI) in CML patients relapsing post-transplant. 8 Lymphocytes collected from the donor are proported to have a highly efficient immune effect because they are not impaired by the immunosuppressive drugs given to the patient and are not inactivated by the tumor escape mechanisms that allow disease relapse. 7 Based on this, DLI is currently used to treat many tumors relapsing after allogeneic transplantation.
The significant association found by Guardiola et al 5 between grades II-IV GVHD after allo-SCT and low treatment failure rate in IM led these authors to suggest a possible graft-versus-IM effect. The findings in our patient (who was also included in the aforementioned study) strongly support the above notion. The patient had IM of advanced histologic stage with poor prognosis features, including the presence of a cytogenetic abnormality, a feature that has been linked to an increased tendency of IM to evolve into acute leukemia. 9 Following allo-SCT, she developed mild GVHD, which was rapidly controlled by immunosuppressive treatment. Although a response to allo-SCT was initially obtained, disease progression was observed a few months later. Because of this, when no effect could be achieved by cyclosporin A discontinuation, DLI was undertaken. Analysis of the sequence of facts observed after the latter measure, with chronic GVHD development followed by long-lasting 'histohematologic' remission of IM, clearly demonstrates the existence of a graft-versus-myelofibrosis effect in this patient. This observation therefore provides a background for designing new therapeutic strategies for IM, such as less intensive transplant modalities, which take advantage of the existence of a graft-versus-disease effect. 10 Further experience will allow the optimum DLI dose for the treatment of post-transplant IM relapse to be defined, as well as the intensity of the conditioning regimen in the setting of future non-myeloablative transplantation protocols.
Note added in proof
Since submission of this paper, Byrne et al (Br J Haematol 2000; 108: 430-433) have reported a 54-year patient in whom remission of IM was achieved following infusion of a lower dose of donor lymphocytes (10 7 /kg CD3 cells), after failure of allogeneic transplantation.
Bone Marrow Transplantation
